Status:

COMPLETED

Phase 1 Study of MKC-1 in Patients With Advanced Cancer

Lead Sponsor:

CASI Pharmaceuticals, Inc.

Conditions:

Advanced Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This is an open-label study to determine the highest dose of MKC-1 that may be administered daily on a continuous basis for patients with advanced or refractory solid tumors.

Eligibility Criteria

Inclusion

  • Have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective.
  • Age greater than or equal to 18 years.
  • ECOG performance status ≤1
  • ANC greater than or equal to 1,500/mm3;
  • Platelets greater than or equal to 100,000/mm3
  • creatinine ≤1.5 times institutional upper limit of normal (ULN)
  • T Bili within normal limits;
  • AST and ALT less than or equal to 2.5 times ULN; and
  • albumin greater than or equal to 3.0 g/dL
  • have measurable disease by RECIST, radiographically evaluable disease, or detectable disease
  • women of child-bearing potential and men must agree to use adequate contraception
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion

  • Have previously received MKC-1.
  • Have received radiation to greater than 25% of the bone marrow.
  • Have had anti-cancer therapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Are concurrently receiving any other investigational agents while on study.
  • Have known brain metastases
  • Have any condition that impairs the ability to swallow and retain MKC-1 capsules.
  • Uncontrolled intercurrent illness
  • Are pregnant or breastfeeding
  • HIV-positive patients
  • Patients with uncontrolled diabetes

Key Trial Info

Start Date :

March 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2009

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT00656461

Start Date

March 1 2008

End Date

November 1 2009

Last Update

November 25 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

U. of Wisconsin Paul P. Carbone Comprehensive Cancer Center

Madison, Wisconsin, United States, 53792